The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 18th 2025
From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.
The Promise of Cancer Immunotherapy: Why Patient Education Is Critical, Part II
April 5th 2016It is imperative that we gather more mature data on a much larger number of patients to accurately assess efficacy, safety, potential harms, durability of response, and impact on disease progression and overall survival of the new immunotherapy treatments.
Read More
Physical Activity Tied to Lower Risk of Mortality After COPD Hospitalization
April 4th 2016Patients with chronic obstructive pulmonary disease (COPD) who engage in greater amounts of physical activity in the 12 months prior to hospitalization for COPD have a lower risk of death in the year following discharge.
Read More
What We're Reading: Medi-Cal Will Be Open to Children in the Country Illegally
April 4th 2016What we're reading: California will open Medi-Cal to all low-income children regardless of immigration status; Arizona governor signs bill to follow earlier FDA guidelines for abortion-inducing drug; and the loss of 2 Obamacare provisions could result in increased premiums in 2017.
Read More
Dr John Thompson Outlines Updates in Melanoma
April 2nd 2016John A. Thompson, MD, co-director of the Melanoma Clinic at the Seattle Cancer Care Alliance, highlighted the major points of his melanoma talk at the National Comprehensive Cancer Network’s 21st Annual Meeting, including the FDA approval of new drugs and the development of new viral therapies.
Watch
Dr Lee Schwartzberg on Updates in Managing Breast Cancer in Older Women
April 2nd 2016There are a number of lessons oncologists have learned as the population of women who were diagnosed with breast cancer at a younger age grow older, said Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center.
Watch
NCCN Has Faith in the Potential of Biosimilars
April 1st 2016While these "generic" biologicals have been deemed to have the potential to create competition and result in healthcare savings-although not to the extent of generic products-technical issues with manufacturing these products have troubled drug manufacturers.
Read More
Despite Progress, CRC Remains Hard-to-Treat Says Expert at NCCN
April 1st 2016At the National Comprehensive Cancer Network (NCCN) 21st Annual Conference, Alan P. Venook, MD, professor of Clinical Medicine at the University of California, San Francisco, provided insight into lessons learned by oncologists in the treatment of colorectal cancer.
Read More
What We're Reading: FTC Files Lawsuit Over Pay-to-Delay Deals
April 1st 2016What we're reading, April 1, 2016: Federal Trade Commission files lawsuit to stop pay-to-delay deals; CMS' bundled payment initiative for joint replacement takes effect; and scientists confirm link between Zika virus and microcephaly.
Read More
What We're Reading: FDA Changes Label for Abortion Pill, Potentially Increasing Access
March 31st 2016What we're reading, March 31, 2016: the FDA changed guidelines for the use of the abortion pill, which could expand access; meanwhile Donald Trump isolated himself by saying women seeking abortion should face punishment; and drug makers are paying less fines for bad behavior.
Read More
A Recommendation for Combining Smoking Cessation Intervention With Lung Cancer Screening
March 30th 2016The Society for Research on Nicotine and Tobacco and the Association for the Treatment of Tobacco Use and Dependence have developed a position statement recommending access to smoking cessation interventions for smokers in the high-risk group who undergo a lung cancer screen.
Read More
Dr Steven Pearson Discusses Increased Scrutiny on Drug Pricing
March 30th 2016As more attention has been drawn to high-cost drugs, the Institute for Clinical and Economic Review has introduced a focus on drug pricing in its reports, explained Steve Pearson, MD, MSc, FRCP, founder and president of ICER.
Watch
The Promise of Cancer Immunotherapy: Why Patient Education Is Critical, Part I
March 29th 2016It is imperative that we gather more mature data on a much larger number of patients to accurately assess efficacy, safety, potential harms, durability of response, and impact on disease progression and overall survival of the new immunotherapy treatments.
Read More
What We're Reading: Valeant Increases Aid-in-Dying Drug Price Ahead of California's New Law
March 24th 2016What we're reading, March 24, 2016: Valeant doubles the price of aid-in-dying drug; the Supreme Court seems split on contraception case; and less than 3% of Americans meet qualifications for a healthy lifestyle.
Read More